A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients

Clinical trial NCT07549321 · RECRUITING

Trial details

NCT number: NCT07549321
Sponsor: Renaissance Pharma Ltd.
Status: RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

High-Risk Neuroblastoma

Start date: 2026-03-30
Primary completion: 2031-03-01
Enrollment: 144

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.